» Articles » PMID: 30734283

In Search of Definitions: Cancer-associated Fibroblasts and Their Markers

Overview
Journal Int J Cancer
Specialty Oncology
Date 2019 Feb 9
PMID 30734283
Citations 339
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment has been identified as one of the driving factors of tumor progression and invasion. Inside this microenvironment, cancer-associated fibroblasts (CAFs), a type of perpetually activated fibroblasts, have been implicated to have a strong tumor-modulating effect and play a key role in areas such as drug resistance. Identification of CAFs has typically been carried based on the expression of various "CAF markers", such as fibroblast activation protein alpha (FAP) and alpha smooth muscle actin (αSMA), which separates them from the larger pool of fibroblasts present in the body. However, as outlined in this Review, the expression of various commonly used fibroblast markers is extremely heterogeneous and varies strongly between different CAF subpopulations. As such, novel selection methods based on cellular function, as well as further characterizing research, are vital for the standardization of CAF identification in order to improve the cross-applicability of different research studies in the field. The aim of this review is to give a thorough overview of the commonly used fibroblast markers in the field and their various strengths and, more importantly, their weaknesses, as well as to highlight potential future avenues for CAF identification and targeting.

Citing Articles

Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance.

Xiao Y, Hassani M, Moghaddam M, Fazilat A, Ojarudi M, Valilo M Med Oncol. 2025; 42(4):108.

PMID: 40087196 DOI: 10.1007/s12032-025-02675-8.


Tumor cell-derived ISG15 promotes fibroblast recruitment in oral squamous cell carcinoma via CD11a-dependent glycolytic reprogramming.

Wang S, Chen Y, Huang S, Fu Y, Lin S, Jiang S Oncogenesis. 2025; 14(1):6.

PMID: 40069143 PMC: 11897235. DOI: 10.1038/s41389-025-00549-2.


Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review.

Liao T, Chen X, Qiu F, Zhang X, Wu F, Zhao Z J Nanobiotechnology. 2025; 23(1):166.

PMID: 40038745 PMC: 11877876. DOI: 10.1186/s12951-025-03217-0.


Assessment of the In Vitro Biological Activities of Schiff Base-Synthesized Copper Oxide Nanoparticles as an Anti-Diabetic, Anti-Alzheimer, and Anti-Cancer Agent.

Almehizia A, Naglah A, Aljafen S, Hassan A, Aboulthana W Pharmaceutics. 2025; 17(2).

PMID: 40006547 PMC: 11859031. DOI: 10.3390/pharmaceutics17020180.


Tumor-derived exosomal KPNA2 activates fibroblasts and interacts with KIFC1 to promote bladder cancer progression, a process inhibited by miR-26b-5p.

Yin C, Liufu C, Ye S, Zhu T, Jiang J, Wang M Cell Mol Biol Lett. 2025; 30(1):20.

PMID: 39956902 PMC: 11830183. DOI: 10.1186/s11658-025-00687-w.


References
1.
Bronzert D, Pantazis P, Antoniades H, Kasid A, Davidson N, Dickson R . Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A. 1987; 84(16):5763-7. PMC: 298943. DOI: 10.1073/pnas.84.16.5763. View

2.
Sugimoto H, Mundel T, Kieran M, Kalluri R . Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006; 5(12):1640-6. DOI: 10.4161/cbt.5.12.3354. View

3.
Stock K, Estrada M, Vidic S, Gjerde K, Rudisch A, Santo V . Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Sci Rep. 2016; 6:28951. PMC: 4929472. DOI: 10.1038/srep28951. View

4.
Grella A, Kole D, Holmes W, Dominko T . FGF2 Overrides TGFβ1-Driven Integrin ITGA11 Expression in Human Dermal Fibroblasts. J Cell Biochem. 2015; 117(4):1000-8. DOI: 10.1002/jcb.25386. View

5.
Herrera M, Islam A, Herrera A, Martin P, Garcia V, Silva J . Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. 2013; 19(21):5914-26. DOI: 10.1158/1078-0432.CCR-13-0694. View